Related Experiment Video
Updated: Jun 13, 2025
Influenza A Virus Studies in a Mouse Model of Infection
Published on: September 7, 2017
Polymyositis and Severe Rhabdomyolysis in the Context of Influenza and COVID-19 Vaccination: A Case Report
Angela Ghiletchi1, Rodrigo Leão2,1, Carolina Coelho1
1Internal Medicine, Centro Hospitalar de Lisboa Central, Lisbon, PRT.
Abstract:
Rhabdomyolysis is characterized by muscle breakdown and the release of muscle enzymes into the bloodstream, which can lead to acute kidney injury (AKI) and electrolyte imbalances. This case report details a 52-year-old male who developed severe rhabdomyolysis and polymyositis following influenza and SARS-COV-2 vaccinations. Presenting with severe muscle pain and elevated creatine kinase (CK) levels, the patient's condition was managed with aggressive hydration and supportive care, resulting in significant recovery. While vaccine-related adverse effects such as myositis and rhabdomyolysis are rare, this case underscores the need for vigilance in monitoring post-vaccination complications and highlights the importance of recognizing and promptly treating vaccine-associated inflammatory myopathies to prevent severe complications. The findings contribute to the growing body of literature on vaccine-induced myopathies and emphasize the necessity of a multidisciplinary approach in managing such complex cases.
Insights
Severe rhabdomyolysis and polymyositis occurred in a patient after influenza and SARS-CoV-2 vaccinations. Prompt treatment led to recovery, highlighting the importance of monitoring for rare vaccine-associated inflammatory myopathies.
Area of Science:
- Neurology
- Immunology
- Nephrology
Background:
- Rhabdomyolysis involves muscle breakdown and enzyme release, potentially causing acute kidney injury (AKI) and electrolyte disturbances.
- Vaccine-induced myopathies are rare but serious potential adverse effects.
Observation:
- A 52-year-old male presented with severe muscle pain and elevated creatine kinase (CK) levels post-influenza and SARS-CoV-2 vaccination.
- The patient was diagnosed with severe rhabdomyolysis and polymyositis.
Findings:
- The patient received aggressive hydration and supportive care.
- Significant recovery was achieved, demonstrating effective management strategies.
Implications:
- This case highlights the need for vigilance in monitoring for rare post-vaccination complications like myositis and rhabdomyolysis.
- Early recognition and multidisciplinary management are crucial for preventing severe outcomes in vaccine-associated inflammatory myopathies.
- Contributes to understanding vaccine-induced myopathies and informs clinical practice.
